Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06088199 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Name: A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis — clinical trial record (NCT06088199)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhasePhase 3

SponsorAmgen

Started2023-10-24

View on ClinicalTrials.gov ↗

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.

Amendment history 1 change detected by DataLookout

2026-08-29

Trial completed

Trial Details

NCT Number	NCT06088199
Lead Sponsor	Amgen
Conditions	Plaque Psoriasis
Enrollment	51 participants
Start Date	2023-10-24
Primary Completion	2026-08-12 (estimated)
Study Completion	2026-08-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-28